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Background: Challenges for steroid analysis by LC–MS/MS include low ionization efﬁciency, endogenous isobars
with similar fragmentation patterns and chromatographic retention. Differential ion mobility spectrometry
(DMS) provides an additional degree of separation prior to MS/MS detection, and shows promise in improving
speciﬁcity of analysis. We developed a sensitive and speciﬁc method for measurement of corticosterone,
11-deoxycortisol, 11-deoxycorticosterone, 17-hydroxyprogesterone and progesterone in human serum
and plasma using an ABSciex 5500 mass spectrometer equipped with a differential ion mobility interface.
Methods: 250 μL aliquots of serum were spiked with deuterated internal standards and extracted with
MTBE. The sampleswere analyzedusing positivemode electrospray LC–DMS–MS/MS. Themethodwas validated
and compared with immunoassays and LC–MS/MS methods of reference laboratories.
Results: Inter and intra assay imprecision was b10%. Limits of quantiﬁcation and detection in nmol/L were 0.18,
0.09 for corticosterone and 17-hydroxyprogesterone, 0.30, 0.16 for 11-deoxycortisol, 0.12, 0.06 for progesterone
and 0.06, 0.03 for 11-deoxycorticosterone. Comparison for progesterone and 17-hydroxyprogesterone with
immunoassay showed slopes of 0.97 and 1.0, intercepts of 0.16 and 0.10 and coefﬁcients of determination (r2)
of 0.92 and 0.97, respectively. Progesterone by immunoassay showed positive bias in samples measuring
b3.18 nmol/L. Reference intervals for progesterone and 11-deoxycorticosterone in post-menopausal women
were found to be b2.88 and b0.28 nmol/L respectively.
Conclusions:We developed and validated an LC–DMS–MS/MS method for analysis of ﬁve endogenous steroids
suitable for routine measurements in clinical diagnostic laboratories. Speciﬁcity gained with DMS allows reducing
the complexity of sample preparation, decreasing LC run times and increasing speed of the analysis.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
Congenital adrenal hyperplasia (CAH) refers to a group of genetic
disorders of steroid biosynthesis in the adrenal glands [1,2]. They are
caused by the inability of the glands to produce enzymes required for
biosynthesis of several steroid hormones, such as glucocorticoids,
mineralocorticoids and sex hormones. Simultaneous measurement of
corticosterone, 11-deoxycortisol (11-DOC-ol), 11-deoxycorticosterone
(DOC) and 17-hydroxy progesterone (17-OHP) is useful in the diagnosis
of these defects and monitoring of patients.
Corticosterone is produced from DOC by the 11β-hydroxylase path-
way. It is further converted to 18-hydroxy corticosterone and ﬁnally to
the important mineralocorticoid, aldosterone. Measurement of cortico-
sterone along with 11-DOC-ol and DOC is used in the diagnosis of
CYP11B1deﬁciency, hyperaldosteronismand11β-hydroxylase deﬁciency
[3,4]. DOC is also used in the diagnosis of suspected 11β-hydroxylase
deﬁciency, differential diagnosis of 11β-hydroxylase 1 (CYP11B1) versus
11β-hydroxylase 2 (CYP11B2) deﬁciency and in the diagnosis of gluco-
corticoid responsive hyperaldosteronism [5,6]. Measurement of 17-OHP
along with cortisol and androstenedione is useful for the diagnosis of
11- or 21-hydroxylase deﬁciencies [3,7]. Progesteroneprimarily produced
in the placenta and corpus luteum, is used to monitor placental function
during pregnancy and ovulation during the menstrual cycle. It is also
used to evaluate patients with adrenal or testicular tumors [8–11].
The steroidsmeasured in this assay have unique biological properties,
while being closely structurally related (corticosterone: 11-DOC-ol and
DOC: 17-OHP being isomeric pairs). Differentiation of these pairs by
LC–MS/MS alone is difﬁcult to achieve due to similar fragmentation
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patterns and chromatographic retentions. The last analyte on the list,
namely progesterone is the most hydrophobic and elutes from the chro-
matographic column at very high percentage of organic modiﬁer, along
with strongly retained and unknown interferences from patient samples.
Failing to resolve these co-eluents in samples with low concentrations of
progesterone could lead to falsely elevated results, which is especially
critical in post-menopausal women [12].
High speciﬁcity and sensitivity are essential for diagnosis of the above
mentioned disorders. Immunoassays (IA) which are commonly used for
steroid analysis are replete with inaccuracies for lack of sensitivity at
low concentrations as well as poor selectivity due to cross reactivity
with antibodies andmatrix effects [13–18]. LC–tandemmass spectrome-
try is increasingly the choice of methodology due to better accuracies by
virtue of improved sensitivity and speciﬁcity [19–23]. In addition to
LC–MS/MSwe evaluated the use of differential ionmobility spectrome-
try towards improving the performance of the assay. DMS (or ﬁeld
asymmetric ion mobility spectrometry, FAIMS) is based on gas-phase
separations at atmospheric pressures and ambient temperature
[24–35]. The Selexion equipped on an ABSciex 5500mass spectrometer
consists of a DMS cell comprised of 2 ﬂat parallel plates (10 × 30 mm,
separated by 1 mm). An asymmetric RF waveform (separation voltage,
SV) is applied to the plates, causing the ions to oscillate, with different
ionic species drifting with different velocities towards one plate or the
other. A DC potential (compensation voltage, CoV) is also applied to
compensate for the net drift of the analyte ions where the ions of the
targeted analytes get resolved from interfering ionic species (Supple-
mental Fig. 1, courtesy Richard A. Yost, University of Florida).
The aim of this work was to develop a highly sensitive and robust
method for quantiﬁcation of the above 5 endogenous steroids in
serum and plasma samples and to evaluate its performance. The novel
method thatwe developed uses DMS in conjunctionwithMS/MS detec-
tion as a way of enhancing speciﬁcity of analysis and reducing the
complexity of sample preparation [31,36–39]. The method has been
fully validated and applied to the analysis of clinical samples.
2. Materials and methods
2.1. Reagents, standards and patient samples
Corticosterone, progesterone and d9-progesterone were purchased
from Cerilliant (Sigma), 11-DOC-ol, DOC, 17-OHP from Sigma, d8-DOC
and d8-corticosterone from CDN Isotopes and d2-11-DOC-ol and
d8-17-OHP from Cambridge Isotope Laboratories, Inc. Stock standards
were prepared inmethanol at concentrations of 1 g/l. Aworking calibra-
tion standard of the analytes was prepared at 144.5 nmol/l for cortico-
sterone and 11-DOC-ol and 151.5, 159.0, 15.1 nmol/l for 17-OHP,
progesterone and DOC respectively in 1:1 methanol: water. Com-
bined working internal standards were prepared at 72.2 nmol/l for
d8-corticosterone and d2-11-DOC-ol and 75.1, 79.5, 18.9 nmol/l for
d8-17-OHP, d9-progesterone and d8-DOC respectively in 1:1 methanol:
water. Calibration standards were prepared in 0.05% BSA at nmol/l
concentrations of 1.4, 2.8, 14.4, 28.9, 57.8, 86.7 for corticosterone and
11-DOC-ol, 1.5, 3.0, 15.1, 30.3, 60.6, 90.9 for 17-OHP, 1.5, 3.1, 15.9, 31.8,
63.6, 95.4 for progesterone and 0.1, 0.3, 1.5, 3.0, 6.0, 9.0 for DOC. Water,
methanol, methyl t-butyl ether (MTBE), iso-propyl alcohol, acetone, ace-
tonitrile and tri-ﬂuoro acetic acid were purchased from VWR (Radnor,
PA). Serum and plasma samples used in the assay were deidentiﬁed dis-
card samples submitted to ARUP Laboratories for routine analysis. All
studies with human serum and plasma samples were approved by IRB
of the University of Utah.
2.2. Sample preparation
Aliquots of 250 μl of calibrators, controls and patient serum/plasma
samples were transferred into 2 ml polypropylene microcentrifuge
tubes. 20 μL of combined working internal standard and 1.5 ml MTBE
were added to each tube, shaken and centrifuged. The organic layer
was transferred to a 96-well plate and evaporated under nitrogen at
50 °C. The residues were reconstituted using 100 μl of 1:1 methanol:
water. The plate was shaken, centrifuged for 5 min at 4000 ×g and the
samples were analyzed by LC–MS/MS.
2.3. LC–MS/MS
Chromatographic separation was performed on a Kinetex C18, 50 ×
3 mm, 2.6 μm particle HPLC column (Phenomenex) ﬁtted with a
Phenomenex Ultra security guard column (C18, 3 mm). The injection
volume was 30 μl and oven temperature was set to 50 °C. The mobile
phase consisted of 10 mmol/l formic acid in water and 10 mmol/l formic
acid in acetonitrile and was delivered at 1 ml/min with a linear gradient
20% to 48% of organic in 3.5 min, followed by a gradient to 75% organic
in 1.6 min. The column was conditioned with 98.5% organic for 1 min
and then equilibrated to initial conditions. Total analysis time per sample
was 6 min. The HTC PAL autosampler (LEAP Technologies,) injection sy-
ringe was washed twice with methanol: water (1:1) with 10 mmol/l
formic acid, and 45% acetonitrile, 45% IPA, 9.4% acetone and 0.6% TFA.
Quadrupoles Q1 and Q3were tuned to unit resolution and theMS pa-
rameters optimized for maximum signal intensity for each mass transi-
tion. The instrument was operated with electrospray ionization in
positive mode; ion-spray voltage was 5500 V, gases 1, 2 and curtain gas
were 60, 50 and 20, respectively; entrance potential (EP) of 10 V, ion
source temperature of 500 °C and a separation voltage (SV) of the Selexion
of 4000V. The declustering potential (DP), collision energies (CE), exit po-
tentials (CXP) and compensation voltages (CoV) of the 2 monitored
MRMs for each analyte are shown in Table 1. The ratio of primary (1) to
secondarymass transition (2)was used to evaluate speciﬁcity of the anal-
ysis. Quantitative calibration was performed with each batch of samples;
data acquisition and processing was performed with AnalystTM 1.5.2.
2.4. Assay performance characteristics
Performance of the assaywas assessed based on imprecision, limit of
detection (LOD), limit of quantiﬁcation (LOQ), upper limit of linearity
(ULOL),method comparison, extraction recovery, carryover, interference
and ion suppression studies. Imprecision of the assaywas determined by
analyzing three replicates of human serum sample pools (low, medium
and high) with concentrations of the analytes ranging between 0.1 and
181.8 nmol/l in one run per day over a period of 20 days. These were
also used as the quality control samples. LOQ was determined by ana-
lyzing 8 samples in triplicate over 6 days; the samples contained
Table 1
Mass transitions and corresponding optimized voltages used in the method.
Mass transitions Q1(Da) Q3(Da) DP(V) CE(V) CXP(V) CoV(V)
Corticosterone-1 347.3 121.1 90 30 15 5
Corticosterone-2 347.3 91.1 90 65 15 5
d8-Corticosterone-1 355.2 125.1 80 41 25 5
d8-Corticosterone-2 355.2 95.1 80 71 25 5
11-DOC-ol-1 347.2 109.1 90 35 10 5.8
11-DOC-ol-2 347.2 97.1 90 31 10 5.8
d2-11-DOC-ol-1 349.3 109.1 140 33 16 5.8
d2-11-DOC-ol-2 349.3 97.1 140 32 10 5.8
DOC-1 331.2 109.1 100 33 13 4.8
DOC-2 331.2 97.1 100 29 11 4.8
d8-DOC-1 339.2 113.1 100 32 25 4.8
d8-DOC-2 339.2 100.1 100 29 25 4.8
17-OHP-1 331.2 109 150 35 13 6
17-OHP-2 331.2 97.1 150 30 11 6
d8-17-OHP-1 339.2 113.1 150 37 13 6
d8-17-OHP-2 339.2 100.1 150 30 11 6
Progesterone-1 315.1 109 90 32 13 5.8
Progesterone-2 315.1 97.1 90 30 11 5.8
d9-progesterone-1 324.2 100.2 90 28 15 5.8
d9-progesterone-2 324.2 113.1 90 31 15 5.8
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progressively lower concentrations of the analytes, and were prepared
by mixing serum pools containing high and low concentration of the
analytes. A stripped serum which had negligible concentrations of
all 5 analytes was used to dilute the high sample pool. The lowest
concentration for which precision was within 15% and observed
concentrations were within 20% of the expected value, was set as the
lower limit of quantitation (LLOQ). Limit of detection (LOD) was deter-
mined as the lowest concentration at which the peaks of the analyte
were present in both mass transitions at the expected retention time
and signal to noise ratio for the quantitative mass transition was ≥5.
Linearity was evaluated by analyzing seven samples in triplicate over
a period of six days. The highest concentration at which precision was
within 10% and accuracy was within 20% of the expected values was
considered to be the upper limit of linearity (ULOL) of the method.
Over 400 patient samples were analyzed during themethod evaluation.
2.5. Method comparison
The method was compared with commercial IAs and LC–MS/MS
methods of referral laboratories. Comparison with Radioimmunoassay
(RIA) was performed for 17-OHP (n= 27); with chemiluminiscent im-
munoassay (CIA) for progesterone (n = 324) and with LC–MS/MS
methods for 17-OHP (n = 32), 11-DOC-ol (n = 31), DOC (n = 20),
corticosterone (n = 50) and progesterone (n = 20). The results for
method comparison and bias estimation were evaluated using Deming
regression.
2.6. Method recovery and carryover
Method recoverywas evaluated by standard addition of the analytes
at 2.89 nmol/l for corticosterone, 11-DOC-ol, 17-OHP and progesterone
and 0.30 nmol/l for DOC in patient samples (n = 5) and analyzed in
duplicate over a period of 2 days. Recovery was estimated from the
difference between the observed and the expected concentrations of
the analytes. Carryover potential for the method was evaluated by
injecting negative controls after samples containing 3.0 to 909.0 nmol/l
of the targeted analytes.
2.7. Interference and Ion suppression
Twenty-three steroids and steroid metabolites were analyzed using
the method to evaluate possible interferences (Supplemental Table 1).
Ion suppression was evaluated by analyzing extracted serum samples
with standards of the analytes infused with a syringe pump at a ﬂow
rate 0.6 ml/h. Concentration of the 5 analytes infused into HPLC efﬂuent
was 50.0 nmol/l; concentration of the targeted analytes in the serum
samples was less than 0.03 nmol/l. A drop in the baseline in the MRM
transitions evidenced ion suppression [40].
2.8. Quality controls
Four controls (negative, low (LQC),medium (MQC) and high (HQC))
analyzed over a period of 20 days were prepared in patient serum pools
by spiking with standards. Acceptability of runs was based on retention
times of the analytes, concentrations of the analytes beingwithin 20% of
historical values and ratios of the primary to the secondarymass transi-
tions N30% being interpreted as presence of interference. Negative
controls were considered acceptable only when concentrations of the
analytes were below LOQ of the method.
2.9. Sample stability and suitability
Stability of the analytes was evaluated over a period of 30 days at
three storage conditions. A sample containing 14.4, 10.6, 12.8, 4.9
and 1.1 nmol/l of corticosterone, 11-DOC-ol, 17-OHP, progesterone
and DOC, respectively, was stored at room temperature (RT), 4 °C
and −20 °C. The tubes were placed in a −70 °C freezer after 1, 3, 7,
14, 21 and 30 days of storage and analyzed in a single batch.
Concentration of the analytes in different collection tubes was eval-
uated in duplicate by using samples from 5 individuals collected in six
types of collection tubes: Li-Heparin, PST, SST, Na-Heparin, Serum and
K2EDTA. Concentrations in the samples were compared within same
individuals.
2.10. Reference interval study for progesterone and DOC in post-menopausal
women
Serum samples were collected from 125 post-menopausal women
(ages 55–89 y;mean 61 y).Whole bloodwas collected in SST vacutainer
tubes and allowed to clot at room temperature for 30 min. Tubes were
centrifuged at 3000 rpm for 10 min, aliquoted, and frozen immediately
at−80 °C. The samples were analyzed for progesterone and DOC. Sta-
tistical data analysis was performed using EP evaluator (v. 9.0; David
G. Rhoads Associates, Inc.).
3. Results
A representative chromatogram of the primaryMRM transition of the
analytes in an extract from a patient sample is shown in Fig. 1; three
periods are shown in separate traces, (A, 0–2.8 min; B, 2.8–3.9 min; and
C, 3.9–6 min). The LLOQs (LODs) of the method were 0.18 (0.09), 0.33
(0.16), 0.18 (0.09), 0.12 (0.06), 0.06 (0.03) nmol/l for corticosterone,
11-DOC-ol, 17 OHP, progesterone and DOC, respectively. Linearity of
the method was found to be 289, 116, 4545, 191, 91 nmol/l for cortico-
sterone, 11-DOC-ol, 17 OHP progesterone and DOC, respectively. Values
of the within-run, between-run and total imprecision are shown in
Table 2. The results of method comparison are presented in Fig. 2A–F.
Method recovery was found to be greater than 95% for all analytes.
No carryover was detected in the blanks and solvents injected after
samples containing very high concentrations of the analytes. None of
the steroids and steroidmetabolites evaluated for potential interference
produced peaks at the retention times of the analytes of interest. There
was no ion suppression at the retention times of the analytes (Supple-
mental Fig. 2).
The 3 controls analyzed with every batch of samples showed ≤20%
imprecision and the ratios of the primary and secondary mass transi-
tions for the analytes in the controls were within the expected limits.
Supplemental Fig. 3 shows results for the three controls per analyte
analyzed over a period of one month. The % CV for LQC, MQC and HQC
were 13, 11 and 11 for corticosterone, 11, 11 and 11 for DOC, 11, 8
and 8 for 11-DOC-ol, 10, 9 and 9 for 17-OHP and 7, 10 and 8 for proges-
terone evidencing ruggedness of the assay.
The 5 analytes, corticosterone, 11-DOC-ol, DOC, 17-OHP and proges-
teronewere found to undergo 12, 21, 41, 15 and 32%degradation, respec-
tively, over a period of 4 weekswhen stored at room temperature. Except
DOCwhich degraded by 20% at the end of 4 weeks at 4 °C, other analytes
were stable under refrigeration for a month. No degradation was
observed in samples stored at−20 °C and−70 °C, and after 3 freeze
thaw cycles. Specimen type evaluation showed that both serum and
plasma samples were acceptable for the test. Concentrations observed
in the patient samples collected in various collection tubes was found
to be b10%.
Reference intervals of progesterone and DOC in post-menopausal
women (n = 125) were established using nonparametric method as
the central 95% of the distribution and determined to be b2.88 and
b0.28 nmol/l respectively (Fig. 3).
4. Discussion
In evaluating the ion mobility technology towards improving the
efﬁciency of the method, we approached the development of the
assay from 2 directions: simpliﬁcation of sample preparation and

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
Author's personal copy
enhancement of speciﬁcity. Earlier published method for 11-DOC-ol,
17-OHP, pregnenolone and 17-hydroxypregnenolone used 2 extrac-
tions (SPE and LLE) in conjunction with derivatization, for enhancing
sensitivity and speciﬁcity of the assay [19].
4.1. Extraction, ionization, HPLC separation
During evaluation of the method we observed an overall reduction
in the signal of all the analytes by approximately 5 times by the use of
DMS. However an efﬁcient extractionmethod such a LLEwhich provided
higher signal of the analytes as well as higher background noise of the
chromatograms was a trade-off for the loss of the signal intensity due
to the use of DMS.
Comparison of the ionization efﬁciencies between ESI and APCI
modes showed approximately 2-fold greater sensitivity for DOC,
11-DOC-ol, 17-OHP and progesterone using ESI while corticosterone
was more efﬁciently ionized using APCI. Aside from the differences in
ionization efﬁciencies among the analytes, HPLC separation also pre-
sented a problem. Progesterone eluted late in the gradient along with
several co-eluting peaks which posed a problem of poor speciﬁcity
especially in samples with low concentration.
LLE in conjunctionwith ESI boosted the signal of the analytes and the
use of DMS overcame the challenges of selectivity and high background
noise, resulting in an assay with simpliﬁed sample preparation. It also
permitted combining all the analytes into a single assay.
4.2. Separation of isomers using DMS
Among the 5 steroids, there are 2 pairs of isomers: corticosterone and
11-DOC-ol (sharing mass transitions m/z 347/96 and 347/91); and DOC
and 17-OHP (sharing mass transitions m/z 331/109 and 331/97). As a
way of enhancing speciﬁcity we evaluated the use of DMS for resolving
peaks of the analytes from coeluting interfering substances. Optimal SV
for all analytes was 4000 V; optimal CoVs were determined by ramping
the DC voltage over a range of −100 to +100 V. While DOC and
17-OHP were well separated by DMS (CoVs of 4.8 V and 6.0 V) and
could be resolved chromatographically, baseline separation of 11-DOC-
ol and corticosterone by LC alonewas somewhat inadequate. To enhance
the selectivity for these 2 analytes,we employed CoV of 5V for corticoste-
rone, and 5.75 V for 11-DOC-ol (Supplemental Fig. 4). Combination of the
partial DMS separation and partial chromatographic separation allowed
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Fig. 1. Representative chromatogram (separated into three time periods) of patient serum sample containing 6.3, 0.3, 2.8, 34.3 and 1.2 nmol/L of corticosterone, 11-DOC-ol, 17-OHP pro-
gesterone and DOC, respectively. The black and white peaks correspond to the quantitative mass transitions of the analytes and the internal standards, respectively. Mass transitions of
corticosterone and 11-DOC-ol were collected during period 1 (A); DOC and 17-OHP during period 2 (B) and progesterone during period 3 (C).
Table 2
Inter and intraassay imprecision.
Sample Mean,
nmol/L
Within run, CV% Between- run/day, CV% Total Imprecision %
Corticosterone
Level 1 1.5 4.6 7.1 8.5
Level 2 30.0 5.0 6.9 8.5
Level 3 115.1 5.4 4.3 6.9
11-DOC-ol
Level 1 1.6 5.5 4.1 6.9
Level 2 60.7 3.1 1.1 3.3
Level 3 138.7 2.4 3.5 4.3
17-OHP
Level 1 1.4 3.7 3.9 5.4
Level 2 15.3 2.7 2.3 3.6
Level 3 59.3 2.6 3.2 4.1
Progesterone
Level 1 1.6 3.0 1.8 3.5
Level 2 101.1 2.0 2.4 3.1
Level 3 126.4 2.5 3.2 4.1
DOC
Level 1 0.1 9.3 5.0 9.9
Level 2 1.5 5.4 2.3 5.9
Level 3 15.9 2.8 2.7 3.9
CV, coefﬁcient of variation.
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4.3. Removal of unknown interferences using DMS
The role of DMS in improving selectivity could be more clearly
assessed by evaluating the performance of themethodwith andwithout
the DMS. As shown in Fig. 4, for samples containing low concentrations
of progesterone or DOC, the DMS effectively removed peaks of interfer-
ing substances from the peaks of interest. Fig. 4B and D demonstrate
the elimination of coeluting peaks with progesterone and DOC at 4.28
and 3.32 min, respectively (a 0.03 min difference in retention time of
progesterone between Fig. 1 and Fig. 4 is attributed to typical variation
in LC retention times between runs). In the experiments without DMS,
the apparent concentrations of progesterone (due to coeluting interfer-
ing peaks) were up to 3 times higher than concentrations in the method
employingDMS (Supplemental Fig. 5). This clearly establishes the utility
of DMS as a tool for resolving peaks of interest from co-eluents, which
becomes especially noticeable in samples containing low concentra-
tions of the analyte.
4.4. Method comparison
The method showed good agreement with LC–MS/MS assays of
other reference laboratories with slopes of Deming regression line of
1.12, 1.08, 0.98, 1.10 and 1.03 and for 11-DOC-ol, 17-OHP, corticosterone,
DOC and progesterone respectively (Fig. 2). 17-OHP measured by RIA
showed good agreement with the current method (slope of regression
line being 1.08). Comparison with CIA method for progesterone
BA C
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Fig. 2. BlandAltmanplots formethod comparisons. A) Comparing11-DOC-olmeasuredby current LC–DMS–MS/MSmethodwith reference laboratory LC–MS/MSmethod.Deming regres-
sion equation: Ref LC–MS/MS = 1.12 ∗ LC–DMS–MS/MS− 0.46, n = 31, r = 0.99, Sy/x = 0.72. B) Comparing 17-OHP measured by current LC–DMS–MS/MS method with reference
laboratory LC–MS/MSmethod. Deming regression equation: Ref LC–MS/MS= 1.08 ∗ LC–DMS–MS/MS+ 0.26, n= 32, r= 0.99, Sy/x= 0.28. C) Comparing 17-OHPmeasured by current
LC–DMS–MS/MS method with reference laboratory RIA method. Deming regression equation: Ref RIA = 1.08 ∗ LC–DMS–MS/MS + 0.32, n = 27, r = 0.97, Sy/x = 2.15. D) Comparing
corticosterone measured by current LC–DMS–MS/MS method with reference laboratory LC–MS/MS method. Deming regression equation: Ref LC–MS/MS Corticosterone = 0.98
∗ LC–DMS–MS/MS + 0.55, n = 50, r = 0.99, Sy/x = 0.72. E) Comparing DOC measured by current LC–DMS–MS/MS method with reference laboratory LC–MS/MS method.
Deming regression equation: Ref LC–MS/MS= 1.10 ∗ LC–DMS–MS/MS− 0.022, n= 20, r = 0.99, Sy/x= 0.07. F) Comparing progesterone measured by current LC–DMS–MS/MSmethod
with reference laboratory LC–MS/MS method. Deming regression equations: Ref LC–MS/MS = 1.03 ∗ LC–DMS–MS/MS + 0.00, n = 20, r = 0.99, Sy/x = 0.31 Divide by 0.029 to convert
nmol/L to ng/dL for corticosterone and 11-DOC-ol, by 0.030 for 17-OHP and DOC and by 3.18 for converting nmol/L to ng/mL for progesterone.
Fig. 3. Histograms with distributions of concentrations of progesterone and 11-deoxycorticosterone in samples from post-menopausal women (n = 125).
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(n = 324) showed a regression line slope of 0.97 and correlation
coefﬁcient of 0.92. However, CIA was overestimating concentration
of progesterone by an average of 2.3 times in samples measuring
b3.18 nmol/l (by the current LC–MS/MS method) (Supplemental
Fig. 6). Considering these ﬁndings, the reported analytical sensitivity
of the CIA method (0.31 nmol/l) could be misleading, especially when
measuring concentrations in samples of post-menopausal women.
Performance of the method validated according to CLSI guidelines
(Supplemental Table 2)was found to be consistent throughout the eval-
uation of the assay, suggesting sufﬁcient robustness of the technique for
use in routine analysis and the practical utility of the hyphenated tech-
nique LC–DMS–MS/MS.
5. Conclusion
We developed an LC–DMS–MS/MS method for analyzing corticoste-
rone, 11-deoxycortisol, 11-deoxycorticosterone, 17-hydroxy progester-
one and progesterone in human serum and plasma that has acceptable
performance characteristics for diagnostic applications. We were able
to reduce background noise, improve performance and separate the
isomeric pairs of analytes by the effective combination of LC and ion
mobility spectrometry. Reference intervals for progesterone and DOC
in post-menopausal women were established. Use of DMS allowed us
to simplify sample preparation, while achieving high speciﬁcity and
sensitivity of analysis, especially in measuring low concentrations of
progesterone in samples from post-menopausal women.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2014.07.036.
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